Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate.
Alison H M Reid, Gerhardt Attard, Daniel C Danila, Nikhil Babu Oommen, David Olmos, Peter C Fong, L Rhoda Molife, Joanne Hunt, Christina Messiou, Christopher Parker, David Dearnaley, Joost F Swennenhuis, Leon W M M Terstappen, Gloria Lee, Thian Kheoh, Arturo Molina, Charles J Ryan, Eric Small, Howard I Scher, Johann S de Bono
文献索引:J. Clin. Oncol. 28(9) , 1489-95, (2010)
全文:HTML全文
摘要
The principal objective of this trial was to evaluate the antitumor activity of abiraterone acetate, an oral, specific, irreversible inhibitor of CYP17 in docetaxel-treated patients with castration-resistant prostate cancer (CRPC).In this multicenter, two-stage, phase II study, abiraterone acetate 1,000 mg was administered once daily continuously. The primary end point was achievement of a prostate-specific antigen (PSA) decline of > or = 50% in at least seven of 35 patients. Per an attained phase II design, more than 35 patients could be enrolled if the primary end point was met. Secondary objectives included: PSA declines of > or = 30% and > or = 90%; rate of RECIST (Response Evaluation Criteria in Solid Tumors) responses and duration on study; time to PSA progression; safety and tolerability; and circulating tumor cell (CTC) enumeration.Docetaxel-treated patients with CRPC (N = 47) were enrolled. PSA declines of > or = 30%, > or = 50% and > or = 90% were seen in 68% (32 of 47), 51% (24 of 47), and 15% (seven of 47) of patients, respectively. Partial responses (by RECIST) were reported in eight (27%) of 30 patients with measurable disease. Median time to PSA progression was 169 days (95% CI, 113 to 281 days). The median number of weeks on study was 24, and 12 (25.5%) of 47 patients remained on study > or = 48 weeks. CTCs were enumerated in 34 patients; 27 (79%) of 34 patients had at least five CTCs at baseline. Eleven (41%) of 27 patients had a decline from at least five to less than 5 CTCs, and 18 (67%) of 27 had a > or = 30% decline in CTCs after starting treatment with abiraterone acetate. Abiraterone acetate was well tolerated.Abiraterone acetate has significant antitumor activity in post-docetaxel patients with CRPC. Randomized, phase III trials of abiraterone acetate are underway to define the future role of this agent.
相关化合物
相关文献:
2010-03-20
[J. Clin. Oncol. 28(9) , 1481-8, (2010)]
2010-03-20
[J. Clin. Oncol. 28(9) , 1496-501, (2010)]
2009-08-10
[J. Clin. Oncol. 27(23) , 3742-8, (2009)]
2015-12-01
[J. Urol. 194(6) , 1537-47, (2015)]
2009-06-15
[Cancer Res. 69(12) , 4937-40, (2009)]